Evidence map›Paper›PMID 38928049›Full record

ArticleInternational journal of molecular sciences2024

Exploring miRNAs' Based Modeling Approach for Predicting PIRA in Multiple Sclerosis: A Comprehensive Analysis.

Tommaso Gosetti di Sturmeck, Leonardo Malimpensa, Gina Ferrazzano, Daniele Belvisi, Giorgio Leodori, Flaminia Lembo, Rossella Brandi, Esterina Pascale, Antonino Cattaneo, Marco Salvetti and 3 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tommaso Gosetti di SturmeckEuropean Brain Research Institute (EBRI) Rita Levi-Montalcini, 00161 Rome, Italy.
Leonardo MalimpensaIRCCS Istituto Neurologico Mediterraneo Neuromed, 86077 Pozzilli, Italy.ORCID 0000-0002-0945-4282
Gina FerrazzanoDepartment of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.
Daniele BelvisiIRCCS Istituto Neurologico Mediterraneo Neuromed, 86077 Pozzilli, Italy.
Giorgio LeodoriIRCCS Istituto Neurologico Mediterraneo Neuromed, 86077 Pozzilli, Italy.ORCID 0000-0002-6631-6740
Flaminia LemboDepartment of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy.
Rossella BrandiEuropean Brain Research Institute (EBRI) Rita Levi-Montalcini, 00161 Rome, Italy.
Esterina PascaleDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy.ORCID 0000-0001-7915-4464
Antonino CattaneoEuropean Brain Research Institute (EBRI) Rita Levi-Montalcini, 00161 Rome, Italy.
Marco SalvettiIRCCS Istituto Neurologico Mediterraneo Neuromed, 86077 Pozzilli, Italy.ORCID 0000-0002-0501-8803
Antonella ConteIRCCS Istituto Neurologico Mediterraneo Neuromed, 86077 Pozzilli, Italy.ORCID 0000-0002-6338-2961
Mara D'OnofrioEuropean Brain Research Institute (EBRI) Rita Levi-Montalcini, 00161 Rome, Italy.
Ivan ArisiEuropean Brain Research Institute (EBRI) Rita Levi-Montalcini, 00161 Rome, Italy.

Funding

Italian Ministry of University and Research Fondo Ordinario Enti (FOE D.M. 865/2019)Italian Ministry of University and Research National Recovery and Resilience Plan (NRRP), project MNESYS (PE0000006)Regione Lazio A0375-2020-36677
6 · The paper itself

Abstract

The current hypothesis on the pathophysiology of multiple sclerosis (MS) suggests the involvement of both inflammatory and neurodegenerative mechanisms. Disease Modifying Therapies (DMTs) effectively decrease relapse rates, thus reducing relapse-associated disability in people with MS. In some patients, disability progression, however, is not solely linked to new lesions and clinical relapses but can manifest independently. Progression Independent of Relapse Activity (PIRA) significantly contributes to long-term disability, stressing the urge to unveil biomarkers to forecast disease progression. Twenty-five adult patients with relapsing-remitting multiple sclerosis (RRMS) were enrolled in a cohort study, according to the latest McDonald criteria, and tested before and after high-efficacy Disease Modifying Therapies (DMTs) (6-24 months). Through Agilent microarrays, we analyzed miRNA profiles from peripheral blood mononuclear cells. Multivariate logistic and linear models with interactions were generated. Robustness was assessed by randomization tests in R. A subset of miRNAs, correlated with PIRA, and the Expanded Disability Status Scale (EDSS), was selected. To refine the patient stratification connected to the disease trajectory, we computed a robust logistic classification model derived from baseline miRNA expression to predict PIRA status (AUC = 0.971). We built an optimal multilinear model by selecting four other miRNA predictors to describe EDSS changes compared to baseline. Multivariate modeling offers a promising avenue to uncover potential biomarkers essential for accurate prediction of disability progression in early MS stages. These models can provide valuable insights into developing personalized and effective treatment strategies.

Indexed as

Disease ProgressionMicroRNAsMultiple Sclerosis, Relapsing-RemittingAdultBiomarkersCohort StudiesFemaleGene Expression ProfilingHumansLeukocytes, MononuclearMaleMiddle AgedMultiple SclerosisRecurrenceBiomarkersMicroRNAsmiRNAmodeling approachmultiple sclerosisprogression independent of relapse activity (PIRA)

Identifiers

PMID38928049
PMCPMC11203572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.